Skip to main content
. 2024 Jun 13;21:138. doi: 10.1186/s12985-024-02410-1

Table 4.

IgA antibody levels against SARS-CoV-2 in responders after infection and vaccination

Infected Vaccinated
N Median [IQR] n Median [IQR] p-value
IgA antibody titres against RBD
 Overall 52 2.97 [1.55; 7.37] 102 2.91 [1.61; 4.94] 0.39
 KTR 17 7.09 [2.28; 10.09] 57 3.11 [1.75; 4.70] 0.009
 HD 18 2.19 [1.45; 6.75] 38 2.99 [1.87; 6.64] 0.54
 Control 17 2.64 [1.60; 5.08] 7 1.46 [1.20; 1.54] 0.01
IgA antibody titres against S1S2
 Overall 60 5.82 [2.75; 14.10] 122 2.29 [1.41; 4.15]  < 0.001
 KTR 19 12.41 [2.78; 21.10] 57 2.43 [1.57; 3.42]  < 0.001
 HD 21 4.66 [2.54; 11.84] 50 2.29 [1.38; 4.32] 0.01
 Control 20 4.41 [2.80; 8.05] 15 1.61 [1.24; 4.15] 0.004

Table showing the IgA antibody titres directed to RBD (upper panel) and S1S2 (lower panel) of SARS-CoV-2 in responders. Time from PCR or first vaccine to blood sample was not correlated with the IgA RBD titres (n = 154, rs = 0.02, p = 0.82) nor IgA S1S2 titres (n = 182, rs = -0.08, p = 0.27). KTR Kidney transplant recipients, HD hemodialysis